Checkpoint inhibitor therapy constitutes a promising cancer treatment strategy that targets
the immune checkpoints to re-activate silenced T cell cytotoxicity. In recent pivotal trials …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …

Importance Checkpoint blockade therapy targeting cytotoxic T-lymphocyte–associated
antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have …

Despite the success of immune checkpoint blockade as a strategy for activating an antitumor
immune response and promoting cancer regression, only a subset of patients have durable …

Immune checkpoint blockade (ICB) therapies, which potentiate the body's natural immune
response against tumor cells, have shown immense promise in the treatment of various …

The development of checkpoint blockade immunotherapy has transformed the medical
oncology armamentarium. But despite its favorable impact on clinical outcomes …

Background The development of immune checkpoint blockade (ICB) has changed the way
we treat various cancers. While ICB produces durable survival benefits in a number of …

Immune checkpoint inhibitors have transformed the prognosis and treatment paradigm of
many cancer types, through the potential for durable responses. However, the majority of …

Molecularly targeted therapy and immunotherapy have dramatically changed the landscape
of available treatment options for patients with advanced cancer. Improved understanding of …

Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint
blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types …